Innovent Biologics (OTCPK:IVBX.F) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IVBX.F 주식 개요

바이오 제약 회사인 Innovent Biologics는 중화인민공화국에서 종양학, 안과, 자가 면역, 심혈관 및 대사 질환 분야에서 단일 클론 항체 및 기타 약물 자산을 개발 및 상업화하는 회사입니다.

IVBX.F 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	5/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 42.4% 에서 거래

수익은 매년 50.81% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 27.1% 증가했습니다.

분석가들은 주가가 44.7% 상승할 것이라는 데 동의합니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

Innovent Biologics, Inc. 경쟁사

Exact Sciences

NasdaqCM:EXAS

US$7.8b

Exelixis

NasdaqGS:EXEL

US$6.5b

ImmunoGen

NasdaqGS:IMGN

US$8.4b

Abcam

NasdaqGS:ABCM

US$5.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Innovent Biologics
과거 주가
현재 주가	HK$4.71
52주 최고치	HK$6.41
52주 최저치	HK$3.55
베타	0.14
11개월 변경	4.84%
3개월 변경 사항	-2.23%
1년 변경 사항	17.98%
33년 변화	-60.44%
5년 변화	n/a
IPO 이후 변화	49.24%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	IVBX.F	US Biotechs	US 마켓
7D	-3.9%	-1.6%	-0.06%
1Y	18.0%	10.4%	20.5%

수익률 대 산업: IVBX.F 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: IVBX.F 지난 1년 동안 22.5 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IVBX.F's price volatile compared to industry and market?
IVBX.F volatility
IVBX.F Average Weekly Movement	8.0%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: IVBX.F 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 지난 1년간 IVBX.F 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다.

회사 소개

설립	직원	CEO	웹사이트
2011	4,872	Michael Yu	www.innoventbio.com

중화인민공화국에서 종양학, 안과, 자가 면역, 심혈관 및 대사 질환 분야에서 단일 클론 항체 및 기타 약물 자산을 개발 및 상용화하는 바이오 제약 회사인 Innovent Biologics는 중국 내 종양학, 안과, 자가 면역, 심혈관 및 대사 질환 분야의 전문 제약 회사입니다. 이 회사는 인간 항 PD-1 단일클론항체 타이비트, 완전 인간 항 VEGF 단일클론항체 바이바스다, 재조합 키메라 쥐/인간 항 CD20 단일클론항체 할프리자 등을 제공합니다; 완전 인간 항-TNF-a 단일클론 항체인 설리노(SULINNO), 선택적 FGFR 억제제인 페마자이어(Pemazyre), 새로운 BCR-ABL TK인 올버렘바티닙(Olverembatinib), VEGF 수용체 2 길항제인 사이람자(Cyramza), 선택적이고 강력한 RET 키나제 억제제인 레세브모(Retsevmo) 등이 개발되고 있습니다. 또한 회사는 완전 인간 BCMA CAR T 세포 치료제인 IBI-326, 경구용 PI3Kd 억제제인 IBI-376, KRASG12C 억제제인 IBI-351, 1/TRK 티로신 키나제 억제제인 IBI-344, CEACAM5 표적 ADC인 IBI-126을 개발 중입니다; 새로운 항단백질 전환효소 서브틸리신/켁신 9형 효소 단일클론 항체인 IBI-306, 글루카곤 유사 펩타이드-1 수용체/글루카곤 수용체 이중 작용제인 IBI-362, 새로운 지속성 항 IL-23인 IBI-112를 개발 중입니다.

Innovent Biologics, Inc. 기본 사항 요약

Innovent Biologics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IVBX.F 기본 통계
시가총액	US$7.67b
수익(TTM)	-US$141.44m
수익(TTM)	US$853.96m

9.0x

P/S 비율

-54.2x

P/E 비율

IVBX.F 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IVBX.F 손익 계산서(TTM)
수익	CN¥6.21b
수익 비용	CN¥1.81b
총 이익	CN¥4.40b
기타 비용	CN¥5.43b
수익	-CN¥1.03b

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.63
총 마진	70.89%
순이익 마진	-16.56%
부채/자본 비율	28.1%

IVBX.F 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IVBX.F 주식 개요

보상

위험 분석

Innovent Biologics, Inc. 경쟁사

NasdaqCM:EXAS

US$7.8b

NasdaqGS:EXEL

US$6.5b

NasdaqGS:IMGN

US$8.4b

NasdaqGS:ABCM

US$5.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Recent updates

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma

Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint

Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V.

Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

Innovent Biologics, Inc. Announces CDE Accepts and Grants Priority Review Designation to New Drug Application

Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint